Showing results (281-290 of 324) with videos related to
Sort By:
Pageof 33
Cancer Discovery|October 20, 2022
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTONRyan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.The New England Journal of Medicine|June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLCShun Lu, Terufumi Kato, Xiaorong Dong, et al.Cancer Research|April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK InhibitorsMi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.Pageof 33